Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 80 points (0.5%) at 15,453 as of Tuesday, Feb. 4, 2014, 11:55 AM ET. The NYSE advances/declines ratio sits at 2,024 issues advancing vs. 894 declining with 170 unchanged. The Health Services industry currently sits up 0.2% versus the S&P 500, which is up 0.7%. Top gainers within the industry include Agilent Technologies ( A), up 1.4%, St Jude Medical ( STJ), up 0.7% and Thermo Fisher Scientific ( TMO), up 0.7%. A company within the industry that fell today was Fresenius Medical Care AG & Co. KGaA ( FMS), up 1.0%. TheStreet would like to highlight 5 stocks pushing the industry higher today: 5. WuXi PharmaTech (Cayman ( WX) is one of the companies pushing the Health Services industry higher today. As of noon trading, WuXi PharmaTech (Cayman is up $1.58 (4.8%) to $34.16 on average volume. Thus far, 259,492 shares of WuXi PharmaTech (Cayman exchanged hands as compared to its average daily volume of 679,300 shares. The stock has ranged in price between $32.63-$34.16 after having opened the day at $32.63 as compared to the previous trading day's close of $32.58. Wuxi PharmaTech (Cayman) Inc., through its subsidiaries, operates as a pharmaceutical, biotechnology, and medical device research and development outsourcing company in China and the United States. It operates in two segments, Laboratory Services and Manufacturing Services. WuXi PharmaTech (Cayman has a market cap of $2.5 billion and is part of the health care sector. The company has a P/E ratio of 23.7, above the S&P 500 P/E ratio of 17.7. Shares are down 15.1% year-to-date as of the close of trading on Monday. Currently there are 7 analysts who rate WuXi PharmaTech (Cayman a buy, no analysts rate it a sell, and 2 rate it a hold. TheStreet Ratings rates WuXi PharmaTech (Cayman as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, impressive record of earnings per share growth and compelling growth in net income. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full WuXi PharmaTech (Cayman Ratings Report now. 3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.